MDT

82.89

+1.38%↑

VEEV

212.71

+0.2%↑

A

102.2

+2.21%↑

WBA

10.96

+1.29%↑

CHE

576

+1.7%↑

MDT

82.89

+1.38%↑

VEEV

212.71

+0.2%↑

A

102.2

+2.21%↑

WBA

10.96

+1.29%↑

CHE

576

+1.7%↑

MDT

82.89

+1.38%↑

VEEV

212.71

+0.2%↑

A

102.2

+2.21%↑

WBA

10.96

+1.29%↑

CHE

576

+1.7%↑

MDT

82.89

+1.38%↑

VEEV

212.71

+0.2%↑

A

102.2

+2.21%↑

WBA

10.96

+1.29%↑

CHE

576

+1.7%↑

MDT

82.89

+1.38%↑

VEEV

212.71

+0.2%↑

A

102.2

+2.21%↑

WBA

10.96

+1.29%↑

CHE

576

+1.7%↑

Search

Fulgent Genetics Inc

Open

SectorHealthcare

18.51 4.46

Overview

Share price change

24h

Current

Min

17.74

Max

18.54

Key metrics

By Trading Economics

Income

9.3M

-6.2M

Sales

4.5M

76M

EPS

0.04

Profit margin

-8.122

Employees

1,313

EBITDA

7.1M

-9.9M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+0.45% upside

Dividends

By Dow Jones

Next Earnings

2 May 2025

Market Stats

By TradingEconomics

Market Cap

73M

585M

Previous open

14.05

Previous close

18.51

News Sentiment

By Acuity

50%

50%

169 / 385 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Fulgent Genetics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

21 Apr 2025, 23:56 UTC

Acquisitions, Mergers, Takeovers

Nomura to Buy Macquarie's U.S., European Public Asset Management Business

21 Apr 2025, 22:37 UTC

Acquisitions, Mergers, Takeovers

Hino Motors, Mitsubishi Fuso Moving Toward Merger, Nikkei Says

21 Apr 2025, 23:58 UTC

Market Talk

Transurban on Bumpy Road During NSW Toll Review -- Market Talk

21 Apr 2025, 23:46 UTC

Market Talk

Gold Rises Amid Likely Safe-Haven Demand -- Market Talk

21 Apr 2025, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

21 Apr 2025, 23:43 UTC

Market Talk

Nikkei May Decline as Uncertainty Over U.S. Trade Policy Continues -- Market Talk

21 Apr 2025, 23:23 UTC

Acquisitions, Mergers, Takeovers

Nomura Expects Transaction to Close by End 2025

21 Apr 2025, 23:22 UTC

Acquisitions, Mergers, Takeovers

Nomura to Pay $1.8B for Macquarie's U.S. and European Public Asset-Management Business

21 Apr 2025, 23:22 UTC

Acquisitions, Mergers, Takeovers

Nomura to Acquire Macquarie's U.S. and European Public Asset-Management Business

21 Apr 2025, 22:35 UTC

Top News

Harvard Is Suing the Trump Administration -- 2nd Update

21 Apr 2025, 22:02 UTC

Top News

Harvard Is Suing the Trump Administration -- Update

21 Apr 2025, 21:46 UTC

Top News

Fed, Tariff Fears Send Dow Down More than 900 Points -- Update

21 Apr 2025, 21:03 UTC

Top News

3M Earnings Will Be Scoured for Tariff Impacts -- Barrons.com

21 Apr 2025, 21:03 UTC

Top News

Harvard Is Suing the Trump Administration -- WSJ

21 Apr 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

21 Apr 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

21 Apr 2025, 20:43 UTC

Top News

GE Aerospace Investors Are Hoping for Reassurance, and Strong Earnings -- Barrons.com

21 Apr 2025, 20:28 UTC

Top News

Fed, Tariff Fears Send Dow Down More than 900 Points -- WSJ

21 Apr 2025, 20:26 UTC

Top News

Lockheed Martin's Earnings Are Coming as Investors Watch the Pentagon -- Barrons.com

21 Apr 2025, 20:24 UTC

Top News

Dow and Dollar Drop on Jitters Over Fed and TradeHeadline -- WSJ

21 Apr 2025, 20:18 UTC

Top News

Boeing 737 MAX Jets in China Head Home. Can They Be Resold? -- Barrons.com

21 Apr 2025, 19:14 UTC

Market Talk

Oil Futures Give Back Pre-Holiday Gains -- Market Talk

21 Apr 2025, 19:11 UTC

Market Talk

U.S. Natural Gas Falls as China Turns Elsewhere for LNG -- Market Talk

21 Apr 2025, 19:07 UTC

Top News

Uber Faces FTC Lawsuit Alleging Deceptive Billing, Cancellation Practices -- Update

21 Apr 2025, 18:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 Apr 2025, 18:44 UTC

Market Talk

Trump Seen as Unlikely to Fire Powell Despite Market Jitters -- Market Talk

21 Apr 2025, 18:28 UTC

Market Talk

Gold Finishes at New Record as Equities Slide -- Market Talk

21 Apr 2025, 18:26 UTC

Top News

Dow Industrials, Dollar Fall on Fed and Trade Concerns -- WSJ

21 Apr 2025, 16:27 UTC

Market Talk

Weaker Dollar No Longer Supporting Commodities Due to Fed Fears -- Market Talk

21 Apr 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

Peer Comparison

Price change

Fulgent Genetics Inc Forecast

Price Target

By TipRanks

0.45% upside

12 Months Forecast

Average 18 USD  0.45%

High 20 USD

Low 16 USD

Based on 2 Wall Street analysts offering 12 month price targets forFulgent Genetics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

2 ratings

0

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

17.655 / 19.08Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

No Evidence

Sentiment

By Acuity

169 / 385 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Fulgent Genetics Inc

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.